What is BiomX?
BiomX operates at the intersection of synthetic biology and clinical medicine, specializing in the development of phage-based therapies. The company's core competency lies in the discovery and validation of proprietary bacterial targets, which are then addressed through customized phage compositions designed to destroy pathogenic bacteria. This mechanism of action offers a highly targeted alternative to traditional broad-spectrum antibiotics, which often disrupt the healthy microbiome. By focusing on chronic diseases—including atopic dermatitis, primary sclerosing cholangitis, and colorectal cancer—BiomX is carving out a distinct market position within the biotechnology landscape. Its ability to engineer phage cocktails allows for a modular approach to drug development, providing a scalable platform that addresses the underlying bacterial drivers of systemic disease.
How much funding has BiomX raised?
BiomX has raised a total of $71.3M across 4 funding rounds:
Series A
$24M
Series B
$32M
Other Financing Round
$12M
Stock/Share Issuance
$3.3M
Series A (2017): $24M with participation from Takeda Ventures, OrbiMed, and JJDC
Series B (2019): $32M, investors not publicly disclosed
Other Financing Round (2025): $12M supported by Cystic Fibrosis Foundation
Stock/Share Issuance (2026): $3.3M, investors not publicly disclosed
Key Investors in BiomX
Takeda Ventures
The corporate venture arm of Takeda Pharmaceutical, focusing on long-term investments in innovative healthcare solutions across gastroenterology, oncology, and rare diseases.
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals and medical devices with deep expertise in life sciences innovation cycles.
Cystic Fibrosis Foundation
A non-profit organization dedicated to funding research and development aimed at curing cystic fibrosis and improving the quality of life for those affected by the disease.
What's next for BiomX?
With the recent $3.3M infusion, BiomX is well-positioned to accelerate its clinical trial milestones and expand its therapeutic reach. The current lifecycle stage, characterized by major enterprise-level funding, suggests a shift toward late-stage clinical validation and potential commercialization readiness. Future strategic initiatives will likely focus on optimizing the manufacturing processes for its phage cocktails and deepening its research into the gut-brain axis and other complex microbiome-related pathologies. As the company continues to refine its proprietary platform, the focus will remain on demonstrating clinical efficacy in pivotal trials, thereby de-risking its pipeline for future partnerships or potential market entry. The ongoing support from its investor base provides the necessary runway to navigate the regulatory complexities inherent in developing novel biological therapeutics.
See full BiomX company page
